Back to results
US 6,583,137 B1Granted
Protease inhibitors
AssigneeSmithKline Beecham Corporation
InventorsRobert Wells Marquis, Jr., Daniel Frank Veber
Life of this patent
Estimating the term…
Abstract
This invention relates to the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvent thereof, which is an inhibitor of cysteine proteases, particularly cathespin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor
Claims17
A compound according to Formula (I):
- (quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[(2,2′,4-trideuterio)-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide), or a pharmaceutically acceptable salt, hydrate or solvate thereof.
A process for the synthesis of the compound of Formula (I):
- comprising the steps:
- (a) of oxidizing the compound of Formula (II):
- with an oxidant to provide the protonated isomer of the compound of Formula (I) as a mixture of diastereomers;
- (b) deuterating the protonated isomer to provide the compound of Formula (I) as a mixture of diastereomers.
1 more element
Dependencies are inferred from the claim text.